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Abstract
Background: Fatty liver disease (FLD) is commonly associated with insulin resistance and obesity, but interestingly it is also
observed at low insulin states, such as prolonged fasting. Thus, we asked whether insulin is an independent modulator of
hepatic lipid accumulation.
Methods/Principal Findings: In mice we induced, hypo- and hyperinsulinemia associated FLD by diet induced obesity and
streptozotocin treatment, respectively. The mechanism of free fatty acid induced steatosis was studied in cell culture with
mouse liver cells under different insulin concentrations, pharmacological phosphoinositol-3-kinase (PI3K) inhibition and
siRNA targeted gene knock-down. We found with in vivo and in vitro models that lipid storage is increased, as expected, in
both hypo- and hyperinsulinemic states, and that it is mediated by signaling through either insulin receptor substrate (IRS) 1
or 2. As previously reported, IRS-1 was up-regulated at high insulin concentrations, while IRS-2 was increased at low levels of
insulin concentration. Relative increase in either of these insulin substrates, was associated with an increase in liver-specific
fatty acid transport proteins (FATP) 2&5, and increased lipid storage. Furthermore, utilizing pharmacological PI3K inhibition
we found that the IRS-PI3K pathway was necessary for lipogenesis, while FATP responses were mediated via IRS signaling.
Data from additional siRNA experiments showed that knock-down of IRSs impacted FATP levels.
Conclusions/Significance: States of perturbed insulin signaling (low-insulin or high-insulin) both lead to increased hepatic
lipid storage via FATP and IRS signaling. These novel findings offer a common mechanism of FLD pathogenesis in states of
both inadequate (prolonged fasting) and ineffective (obesity) insulin signaling.
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Introduction
The incidence of obesity continues to grow, bringing with it an
increased prevalence of non-alcoholic fatty liver disease (NAFLD)
[1]. While the cause of hepatic steatosis is unknown, obesity-
associated hyperinsulinemia is a logical candidate. Nonetheless,
the link between insulin and the liver’s handling of lipids is not
completely understood and likely is more complex than a simple
linear relationship. For instance, NAFLD is also increased in states
of low insulin such as poorly controlled type-1 diabetes (T1DM)
[2,3] and prolonged fasting [4,5].
Insulin receptor substrates (IRS) are well-described intracellular
docking molecules that bind to the insulin receptor and initiate the
canonical insulin signaling pathway [6]. Findings from knockout
mice suggest that most insulin responses associated with nutrient
homeostasis are mediated through IRS-1 and/or IRS-2 [7]. IRS-1
is induced in high insulin conditions including the post-prandial
state [8] and obesity, whereas IRS-2 is increased in low insulin
states such as fasting [9,10,11] and caloric restriction [12,13]. This
information, together with the understanding that both high and
low insulin states also trigger liver lipid accumulation [2–5], begs
the question as to whether the relative level of insulin and its
concomitant IRS signaling is causally related to the accumulation
of lipids in the liver.
To address this question, we focused on fatty acid transport
proteins (FATPs) as downstream targets of IRS signaling, since
these molecules putatively transport free fatty acids (FFAs) into the
cell [14] and are therefore likely intermediaries of hepatic steatosis
[15]. Further, FATPs are not exclusively plasma membrane bound
and are also found to increase fatty acid transport when present
intra-cellularly including on the endoplasmic reticulum and some
data suggest that at least in adipocytes FATP1 may translocate to
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upon insulin stimulation [16,17,18]. Of the various FATPs, FATP-
5 is found exclusively in the liver [19], while FATP-2 is found in
liver and kidney [20]. Deletion of either FATP-2 [21] or FATP-5
[22,23,24] in mice results in decreased hepatic steatosis. In
addition, these transporters are up-regulated in the livers of
patients with NAFLD [25,26,27]. Our overarching hypothesis was
that high or low of insulin concentration may trigger the IRS-1 or
2 signaling and consequently activate FATP-2 & 5 mediated fatty
acid transport, thus contributing to hepatic lipid accumulation.
Materials and Methods
Ethics Statement
All animal studies were approved by the Institutional Animal
Care and Use Committee at Cincinnati Children’s Hospital,
Cincinnati, Ohio viz. protocol ID number 0D10081.
Mouse Model of Fatty Liver Disease with
Hyperinsulinemia- Type 2 Fatty Liver Disease (T2FLD)
Adult male C57Bl/6 mice (Jackson Laboratory, Bar Harbor,
ME) were group-housed 4/cage (2262uC) on a 12-hour light-dark
cycle. Animals were randomized to chow (Teklad-Harlan,
Madison, WI), or high-fat high-carbohydrate (HFHC) diet (Surwit
diet, 58 kcal % fat; Research Diets, New Brunswick, NJ) and
drinking water with high fructose (55% fructose by weight; Acros
Organics, Morris Plains, NJ) and sucrose (45% sucrose by weight;
Sigma-Aldrich, St. Louis, MO) at a concentration of 42 g/L [28].
Animals were provided ad-lib access to diets for 12 weeks. Body
weights and food intake were recorded.
Mouse Model of Fatty Liver Disease with
Hypoinsulinemia- Type 1 Fatty Liver Disease (T1FLD)
The same strain, age, and gender of mice were utilized under
identical conditions as mice in T2FLD model. Mice were kept on
chow or high-fat diet (HFD; 60% kcal predominantly palmitic,
stearic and oleic fatty acids -Research Diets, New Brunswick, NJ)
for 2 weeks. After two weeks a group of chow and HFD mice were
injected ip with 200 mg/kg Streptozotocin (Sigma-Aldrich, St.
Louis, MO), dissolved in Citric acid buffer, pH=4.2. Mice were
sacrificed three days after STZ injection.
T1FLD (Mouse Model of Fatty Liver with
Hypoinsulinemia) Mice Treated with Exogenous Insulin
Replacement
Mice were treated as in T1FLD model with following
exceptions. Three days after STZ injection blood glucose was
measured after 4 hour fast (Roche Diagnostics, Indianapolis, IN).
Animals in HFD, STZ treated group with glucose values
.250 mg/dl were assigned into three groups. Group 1 was i.p.
injected with normal saline (NS) 200 ml/mouse, group 2 received
20, while group 3 received 200 mU/mouse of insulin (Lantus
TM,
Sanofi-Aventis, Bridgewater, NJ), dissolved in 200 ml of NS. After
insulin injection mice were sacrificed after a 12 fast.
Plasma Free Fatty Acids
12 hour fasting plasma samples from T1FLD mice treated with
exogenous insulin replacement were analyzed for total free fatty
acid content using a weighed sample of 100 mL of plasma and
10 mg of heptadecanoic acid in hexane solution. Samples were
saponified with methanolic NaOH and methylated with BF3 in
methanol according to the method of Metcalfe et al. [29]. Samples
were extracted from the aqueous phase and then analyzed by gas
chromatography as described earlier. [30].Fatty acids were
identified and total mass quantified based on the mass of the
added heptadecanoic acid standard.
Histology
Harvested livers were submitted to the Department of
Pathology at Cincinnati Children’s Hospital Medical Center for
hematoxylin & eosin (H&E) staining and preparation of frozen
sections.
Cell Culture Model of Steatosis
We used a previously established cell culture model of hepatic
steatosis induced by feeding 1 mM (2:1) oleate (Sigma-Aldrich, St.
Louis, MO)/palmitate (Sigma-Aldrich, St. Louis, MO) mixture to
TGF-a immortalized mouse hepatocytes (AML12 cells, ATCC,
Manassas, VA) [31]. In brief, cells were grown for 48 hours, made
quiescent by growing them in cell-culture media without fetal
bovine serum for 24 hours and subsequently treated with different
concentrations of insulin (0, 2.5, 10, 20, 50 and 100 mU/ml
{100 mU/ml being equivalent to 0.69 mM or 4.0 mg/ml}) for 24
hours, then harvested after FFA (1:100 dilution) exposure for 12
hours. In some experiments, 50 uM LY294002 (PI3K inhibitor)
was added to AML12 cells 12 hours prior to addition of FFA
enriched medium.
Oil Red-O Staining
Cultured hepatocytes grown in 12 well plates on glass cover slips
were stained using oil red-O kit (American MasterTech, Lodi,
CA). Similar staining was performed on T2FLD and T1FLD liver
frozen sections.
Triglyceride (TG) and Alanine Amino Transferase (ALT)
Quantification
Intracellular TG content was determined from harvested cells
and/or mouse liver homogenates as previously described [32].
Briefly, 100 milligrams of wet liver tissue or a monolayer of plated
cells were homogenized in a 20 mM Tris buffer. Triglyceride
reagent set (Pointe Scientific, Canton, MI) was used for the assay
per manufacturer’s instructions. Photometric absorbance was read
at 500 nm using Synergy 2 microplate reader (BioTek, Winooski,
VT). ALT was measured from cell supernatant or mouse serum
utilizing DiscretPak
TM ALT Reagent Kit (Catachem, Bridgeport,
CT). ALT enzyme kinetics was measured over a five minute
interval by measuring change in photometric absorbance at
340 nm.
qPCR Gene Expression
RNA was isolated from cultured cells and/or frozen liver
tissue. Initially, the samples were homogenized in a 20 mM Tris
buffer. Total RNA was isolated using TRIzolH reagent protocol
(Molecular Research Center, Cincinnati, OH). cDNA was made
using TaqMan
TM Reverse Transcription protocol (Applied
Biosystems, Carlsbad, CA) on an Eppendorf Mastercycler PCR
machine (Eppendorf North America, Westbury, NY). Gene
specific primer sequence 59 to 39 ends is as follows: GAPDH
forward TGGTTTGACAATGAATACGGCTAC reverse
GGTGGGTGGTCCAAGGTTTC, FATP-2 forward
ACTGCTCAAACTGGGCTGTC reverse TGGAA-
GAACCTCCTCCACAG, FATP-5 forward ACTCTGTACG-
GAGCTCTGGG reverse GAGCTGTGGCCAAGGTAGAA,
IRS-1 forward GCCAGAGGATCGTCAATAGC reverse
AGGTCCTGGTTGTGAATTGTG, IRS-2 forward
Insulin and Hepatic Fatty Acid Transport
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GAGCGCGATCAC.
Messenger RNA expression was measured using Stratagene
SYBRH green real-time kinetic PCR on a Stratagene Mx-3005
Multiplex Quantitative PCR machine (Stratagene, Agilent Tech-
nologies, La Jolla, CA). The standard curve method was utilized to
calculate relative gene expression.
RNAi Cell Culture Experiments
AML-12 cells were grown to 80% confluence as above, then
transfected according to manufacturer’s protocol. In brief, Opti-
MEMH (Invitrogen, Carlsbad, CA) at a final volume of 250 mL
each was used to prepare Lipofectamine
TM 2000 (Invitrogen,
Carlsbad, CA) and IRS1 & 2, FATP 2 & 5, small interference (si)
RNA in 6 well plates. The complex was added to the well with
1.5 mL of medium without antibiotics and incubated at 37uC for
12 hours. siRNA oligomers (Invitrogen, Carlsbad, CA) used
were: IRS1, sense sequence GGUCAGACAAAGAACCUGAtt
and antisense sequence UCAGGUUCUUUGUCUGACCca;
IRS2, sense sequence UCAUGUCCCUUGACGAGUAtt and
antisense sequence UACUCGUCAAGGGACAUGAaa; FATP2
(Slc27a), sense sequence CAUCAAUCAUCAUCGCCUAtt and
antisense sequence UAGGCGAUGAUGAUUGAUGgt; FATP5
(Slc27a5), sense sequence GCUACGAUUAAGUGGAAAUtt
and antisense sequence AUUUCCACUUAAUCGUAGCtc.
Following transfection, the media was changed and the cells
were made quiescent for 24 hours and subsequently fed FFA for
12 hours. Following purification of total RNA and synthesis of
cDNA, real-time PCR analysis was performed with pre-designed,
validated gene-specific TaqManH probes (Applied Biotechnology,
Carlbad, CA). Relative expression was determined by normal-
izing to GAPDH expression. Primer probe sets used to evaluate
gene knockdown on gels were: Mm01278327_m1(IRS1);
Mm03038438_m1(IRS2); Mm00449517_m1(FATP2);
Mm00447768_m1(FATP5); Mm99999915_g1(GAPDH).
FATP-2 Immunofluorescence
Cells were grown on cover-slips and treated as outlined above in
the in vitro cell culture steatosis model. Thereafter they were fixed
in ice cold acetone, blocked in 5% BSA solution and stained with
primary antibody against FATP-2 (Abcam, Cambridge, MA) and
secondary anti-mouse FITC antibody (Abcam, Cambridge, MA).
Images were taken on a Zeiss epifluorescence microscope (Zeiss,
Pleasanton, CA).
Statistical Analysis
Results are expressed as mean 6 SEM. Where indicated, the
statistical significance between two groups was estimated by
Student’s t test or among three or more groups using ANOVA. *,
**, *** and indicate statistical significance with p,0.05, p,0.01
and, p,0.001 respectively. Statistically non-different results were
labeled ns where appropriate.
Results
In vivo Models of Streptozotocin Induced
Hypoinsulinemia (T1FLD) and Diet Induced
Hyperinsulinemia (T2FLD) both Result in Hepatic
Steatosis
To test the effect of hypoinsulinemia on liver TG accumulation
we injected mice, that had been fed a HFD for 2 weeks, with
streptozotocin to ablate insulin producing pancreatic b-cells i.p. as
described before [33] (T1FLD). To address the effect of
hyperinsulinemia on liver TG accumulation, we placed mice on
a HFD for 12 weeks as previously described [28] (T2FLD).
At sacrifice, T1FLD mice weighed the same as controls
(Figure 1A), but had developed fasting hyperglycemia and
hypoinsulinemia resulting in a significant reduction in HOMA-
IR (Figure 1B). Despite their unchanged body weight these
hypoinsulinemic mice had increased liver to body weight ratio
(Figure 1C), H&E staining indicative of steatosis (Figure 1D) and
increased serum ALT (Figure 1E) relative to chow fed-saline
injected controls. This was further matched by increased oil red-O
staining (Figure 2A) and liver TG accumulation (Figure 2B).
Interestingly, the STZ injected T1FLD mice had hepatic steatosis
but with low circulating plasma insulin levels they had a reduced
liver pAkt to total Akt ratio (Figure 2C).
In comparison when T2FLD were sacrificed they had gained
more weight than chow-fed control mice (Figure 1F), and had
developed fasting hyperglycemia, and hyperinsulinemia, resulting
in a significant increase in HOMA-IR (Figure 1G).These mice also
had increased liver weight (Figure 1H), H&E staining indicative of
steatosis (Figure 1I), and increased serum ALT (Figure 1J).
Furthermore, these mice had increased steatosis on Oil Red-O
(Figure 2A) and increased intracellular TGs (Figure 2B). This high-
fat diet fed murine model which induced hepatic steatosis with
hyperinsulinemia, was also associated with increased liver pAkt to
total Akt ratio by western blotting (Figure 2C).
Increased IRS-2 in T1FLD and Increased IRS-1 in T2FLD
are Associated with Augmented FATP Expression and
Protein Levels
Hypoinsulinemic T1FLD mice had increased levels of IRS-2
hepatic gene expression, which was absent in T2FLD mice
(Figure 2D). Conversely, liver IRS-1 mRNA expression levels were
increased in T2FLD mice, without significant change in T1FLD
mice (Figure 2E).
Both T1FLD and T2FLD mice livers had an increase in FATP-
2 mRNA (Figure 2F) and protein levels (Figure 2G), as well as
FATP-5 mRNA expression (Data not shown). Thus, in vivo
hypoinsulinemic T1FLD mice developed hepatic steatosis, which
was associated with an up-regulation of IRS-2 relative to IRS-1,
and an increase in FATP-2 and FATP-5 mRNA expression, as
well as greater FATP-2 protein levels.
Conversely, in-vivo HFD induced hyperinsulinemic T2FLD
mice were associated with an up-regulation of IRS-1 relative to
IRS-2 (Figure 2 D and E), and an increase in FATP-2 (Figure 2 F)
and FATP-2 protein (Figure 2 G), as well as greater FATP-5
mRNA expression (Data not shown).
Insulin Replacement to Hypoinsulinemic Mice on HFD
(T1FLD) Reduces Fatty Liver
When considered together, the data from our two in vivo mouse
models indicate that either high or low insulin levels lead to
steatosis, while normoinsulinemic mice do not develop excessive
liver lipid accumulation. To determine whether insulin levels in vivo
can modulate liver lipid accumulation, we treated a group of
hypoinsulinemic T1FLD mice with increasing doses of insulin
(Lantus
TM) for 12 hours. As before, prior to insulin replacement
the mice were hyperglycemic (Figure 3A). This hyperglycemia was
reversed by insulin replacement in a dose-dependent manner
(Figure 3B) resulting in progressively elevated insulin levels
(Figure 3C). Plasma free fatty acid levels were also decreased in
a dose dependent manner with increasing insulin administration
(Figure 3D).
Insulin and Hepatic Fatty Acid Transport
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decrease in steatosis by oil red-O (Figure 4A). This was also
reflected in liver TG quantification (Figure 4B). FATP-2
(Figure 4C) and FATP-5 (Figure 4D) mRNA expression levels
were decreased after insulin treatment, as was FATP-2 liver
protein (Figure 4E). Thus exogenous insulin decreased both
circulating FFA and liver fatty acid transport related proteins. This
experiment confirmed that liver TG accumulation in T1FLD mice
can be reversed by exogenous insulin and it is associated with the
down regulation of FATP-2 and FATP-5 i.e., reversal of the
insulin deficiency resulted in reversal of liver TG accumulation.
Insulin Modulates Triglyceride Accumulation and FATP
Expression in vitro
Hepatocytes were cultured in the presence of basal levels of
insulin and fed FFA. Relative to control cells, FFA-enriched cells
had increased oil red-O staining (data not shown), as well as
increased intracellular TG content (data not shown) and
supernatant ALT (data not shown). These findings were consistent
with our and other previous reports [31,34].
Variation of insulin concentration in the above setting resulted
in a U-shaped bimodal function of positive oil red-O staining
(Figure 5A), that paralleled hepatic TG accumulation (Figure 5B).
The most intense staining and peak hepatocyte TG content
occurred at the lowest and highest concentrations of added insulin
(0 and 100 mU/ml, respectively), while the nadir was observed at
10 mU/ml. For cells incubated in the absence of added FFA, there
was no dose-effect TG accumulation in response to added insulin
alone (data not shown). Further, supernatant glucose levels were
not changed for insulin-treated cells (data not shown), in
agreement with previous reports indicating that insulin does not
stimulate glucose uptake in the liver [35]. These data suggest that
Figure 1. In vivo model of hypoinsulinemia on high-fat diet leads to fatty liver disease. (A) Weight in grams after two weeks of chow
(Chow) or high-fat diet, followed by streptozotocin injection (T1FLD). (B) HOMA-IR at sacrifice (C) Liver to body weight ratio. (D) H&E stain of
representative liver sections and (E) serum ALT levels. In vivo model of hyperinsulinemia on high-fat diet leads to fatty liver disease. (F) Weight
change of chow (Chow) and high fat diet fed mice (T2FLD) after 12 weeks on respective diets. (G) HOMA-IR, a measure of insulin resistance and (H)
liver weight from the same mice. (I) H&E stain of representative liver sections and (J) serum ALT levels. [*P,0.05, **P,0.01 & ***P,0.001, n=4–6 for
chow, 5 for T1FLD and 6 for T2FLD. Representative of two-three replicate experiments.]
doi:10.1371/journal.pone.0038952.g001
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accumulation in the liver, glucose utilization is unlikely to mediate
its U-shaped effect.
To assess whether insulin-mediated FFA transport may be
a factor, we measured the expression of FATPs in vitro.A
comparable bimodal insulin-response curve occurred for FATP-2
(Figure 5C) and FATP-5 (Figure 5D) mRNA, as well as for FATP-
2 protein immunofluorescence (Figure 5F). We used siRNA
against FATP-2 & 5 and observed an almost 50% reduction in TG
accumulation with either FATP-2 or 5 knock-down (Figure 5E).
Simultaneous knock-down of both FATP-2 & 5, resulted in an
almost complete normalization of hepatocyte TG levels. These
experiments further confirmed that FATP expression is sensitive to
insulin, and that the consequent U-shaped function of TG
accumulation mimics a change in FATP-2 & 5 mRNA levels.
In vitro IRS-1 and IRS-2 Expression is Dependent on
Insulin Concentration
Our in vivo studies suggest that IRS substrates may be
differentially expressed at extremes of insulin concentrations.
Thus, IRS expression was again assessed in cell culture model of
steatosis and increased IRS-2 (Figure 5G) mRNA levels were
found at low insulin concentrations, while our highest insulin
condition resulted in increased IRS-1 (Figure 5H) mRNA. In
addition, a small but significant rise in IRS-1 was also observed at
low insulin conditions however this in vitro increase in IRS-1 at low
insulin levels was not observed in our in vivo studies. To further test
whether changes in IRS expression are implicated in lipogenesis,
we inhibited its downstream target PI3K with LY294002 (LY). A
marked reduction in TGs was seen with LY, regardless of insulin
concentration (Figure 5I). This suggested that TG accumulation in
both hypo and hyperinsulinemia converges onto a common PI3K
dependent pathway.
In vitro Inhibition of IRS Mediated FATP Expression Leads
to Decreased TG Accumulation
A stronger link between IRSs and FATPs was further
established in experiments using siRNA inhibition of IRS-1 & 2.
FATP-2 mRNA expression at 0 mU/ml insulin decreased after
both IRS-1&2 knock-down, while at 100 mU/ml insulin only
IRS-1 knock-down resulted in a significant decrease in FATP-2
mRNA (Figure 6A & B). Similarly, FATP-5 mRNA at 0 mU/ml
insulin decreased after both IRS-1 & 2 knock-down, while at
100 mU/ml insulin only IRS-1 knock-down resulted in a signifi-
cant decrease in FATP-5 mRNA (Figure 6C & D). Analogous to
this decrease in FATPs, IRS-1 & 2 knock-down at 0 mU/ml
insulin resulted in a decrease in hepatocyte TG content, while only
IRS-1 knock-down at 100 mU/ml insulin resulted in a decrease in
hepatocyte TG accumulation (Figure 6E & F). Thus, inhibition of
IRS-1 or IRS-2 at states of their respectively augmented
expressions leads to decreased FATP expression and subsequent
reduction in hepatic TG accumulation.
Figure 2. In vivo models of hypoinsulinemia on HFD (T1FLD) and hyperinsulinemia on HFD (T2FLD) lead to fatty liver disease. (A) Oil
red-O staining (red) of representative liver sections scale bar=100 mm of chow fed(Chow), mice fed HFD for 2 weeks and then streptozotocin injected
for three days (T1FLD) and HFD fed mice for 12 weeks (T2FLD). (B) TG content per 100 mg of liver tissue in Chow, T1FLD, and T2FLD mice (C) Liver
pAkt of Chow, T1FLD, and T2FLD mice (D) Liver IRS2 mRNA expression normalized to 18s ribosomal protein in Chow, T1FLD, and T2FLD, (E) Liver IRS1
mRNA expression normalized to 18s ribosomal protein in Chow, T1FLD, and T2FLD (F) Liver FATP2 mRNA expression normalized to 18s ribosomal
protein in Chow, T1FLD, and T2FLD, (G) Liver FATP2 protein on Western Blot normalized to b-actin in Chow, T1FLD, and T2FLD, [One way ANOVA
with Tukey’s post-hoc test *P,0.05, **P,0.01 & ***P,0.001; n=5–8 per group, representative of three replicate experiments.]
doi:10.1371/journal.pone.0038952.g002
Figure 3. Insulin replacement to hypoinsulinemic mice (T1FLD) reduces plasma glucose and free fatty acids (FFA). (A) Fasting blood
glucose of T1FLD mice generated as before (Figure 1 and 2) (B) and 12 hours after incremental Lantus replecement (0, 20 & 200 mU/mouse). (C)
Plasma insulin and (D) FFA levels following Lantus treatment were reduced. [***P,0.001, n=7 per group, representative of one experiment.]
doi:10.1371/journal.pone.0038952.g003
Insulin and Hepatic Fatty Acid Transport
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Our in vivo models of hepatic steatosis with perturbed insulin
concentrations had relatively increased IRS-1 expression at high
insulin concentrations (T2FLD), and relatively increased IRS-2 at
low insulin concentrations (T1FLD) (Figure 6G). This relative
‘imbalance’ between the two IRS molecules was associated with an
up-regulation of FATP-2 & 5 in both states. Holding other
parameters constant in vitro, we replicated this bimodal TG
accumulation function simply by varying insulin levels. We thus
describe a novel insulin driven bimodal FATP-lipid accumulation
response.
FATP (later named FATP1) was first identified in 1994 by
Schaffer et al and shown to increase the uptake of long chain fatty
acids across the plasma membrane [36]. The murine Fatp1 gene
was found to span approximately 16 kilobases and contain 13
exons, of which exon 2 was shown to be alternatively spliced. Since
then multiple groups have worked on various isoforms of FATP in
different tissues of interest. Further, human relevance has been
described and researched in the setting of X-linked adrenoleuko-
dystrophy, a genetic neurodegenerative disorder wherein in-
creased levels of saturated very long-chain fatty acids are found
in tissues and plasma. Herein FATP2 has independently been
identified as a hepatic peroxisomal very long-chain acyl-CoA
synthetase [21,37]. Further, in adipocytes FATP1 has been shown
to be transcriptionaly regulated by insulin [38]. Thus, given the
putative role of FATPs in hepatic lipid transport and their
potential to be regulated by insulin in other tissues we set about
looking into the link between insulin and lipid transport and its
relation to FATP 2 and 5 in the liver.
Investigating the hyperinsulinemic state Kerouz et al. have
reported that obese ob/ob mice have significantly higher IRS-1
than IRS-2 liver protein [39]. Furthermore, Guo et al. reported
that inactivation of IRS-1 leads to improvement in murine hepatic
steatosis [40]. Further, Taniguchi et al. found that short term
adenovirus mediated inactivation of IRS-2 increased hepatic
steatosis [41]. Thus, we conclude from the literature our data that
an imbalance of IRS signaling favoring relatively more IRS-1 than
IRS-2 occurs in the hyperinsulinemic state.
Figure 4. Insulin replacement to hypoinsulinemic mice (T1FLD) reduces fatty liver. (A) Oil Red-O staining (red) and hematoxylin (blue) of
representative liver sections, scale bar=100 mm for T1FLD provided with Lantus
TM replacement (0, 20 & 200 mU/mouse) for 12 hours and (B)T G
content per 100 mg of liver tissue in T1FLD provided with Lantus
TM replacement (0, 20 & 200 mU/mouse) for 12 hours. (C) Liver FATP-2 mRNA
expression in T1FLD mice with Lantus
TM replacement (0, 20 & 200 mU/mouse) for 12 hours. (D) Liver FATP-5 mRNA expression in T1FLD mice with
Lantus
TM replacement (0, 20 & 200 mU/mouse) for 12 hours. (E) Liver FATP-2 western blot normalized to b-actin in T1FLD mice with Lantus
TM
replacement (0, 20 & 200 mU/mouse) for 12 hours. [One way ANOVA with Tukey’s post-hoc test *P,0.05, **P,0.01, ***P,0.001, n=5–6 per group.]
doi:10.1371/journal.pone.0038952.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38952Figure 5. Insulin mediates triglyceride accumulation and FATP expression in vitro via IRS-1 and IRS-2 expression. (A) Oil Red-O stain
(red) for lipids and hematoxylin nuclear stain (blue) of AML-12 hepatocytes fed FFA for 12 hours in varying insulin concentrations (0, 2.5, 10, 20, 50
and 100 mU/ml). Original magnification6400. (B) Intracellular TG quantification as well as (C) FATP-2 & (D) FATP-5 mRNA expression of hepatocytes.
(E) qPCR (bar graph) results of targeted gene knockdown using scrambled and FATP2 siRNA at 50 pmol concentration; efficient knockdown was
confirmed by running PCR reactions on an agarose gel. (F) qPCR (bar graph) results of targeted gene knockdown using scrambled and FATP5 siRNA
at 50 pmol concentration; efficient knockdown was confirmed by running PCR reactions on an agarose gel. (G) TG quantification following targeted
gene knock-down against Scrambled, FATP-2, FATP-5, or both FATP-2 & FATP-5. (H) Immunofluorescently labeled FATP-2 protein (green) counter
stained with DAPI (blue) nuclear stain treated as in panel A. (I) IRS-2 & (J) IRS-1 mRNA expression of AML-12 hepatocytes fed FFA for 12 hours in
varying insulin concentrations (0, 2.5, 10, 20, 50 and 100 mU/ml). (K) TG accumulation of FFA fed cells with (+) or without (2) 50 uM LY294002 (LY).
Data for without LY also shown in Fig 4B. [ANOVA *P,0.05, **P,0.01 & ***P,0.001; n=6 per group, representative of three replicate experiments.]
doi:10.1371/journal.pone.0038952.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38952Investigating the hypoinsulinemic state Rojas et al. observed that
liver IRS-2 protein increased relative to IRS-1 after a 72-hour fast
or with STZ-induced T1DM [42]. Contrary to these findings,
Simmgen et al. reported that IRS-2 signaling is not required for
hepatic lipid metabolism [43]. However, the authors of these
studies did not assess this in either fasting or STZ-induced
conditions, where IRS-2 is shown to be increased. We observed in
our insulin replacement experiment a dose dependent reduction in
liver TG content in STZ treated T1FLD mice receiving insulin.
Interestingly we also observed a significant decrease in fasting FFA
plasma levels associated with increasing exogenous insulin doses.
Though we did not measure fatty acid transport directly in our
current experiments this is clearly an important path of future
research. This decrease in FFA maybe a manifestation of direct
insulin mediated reduction in peripheral lipolysis and therefore
contribute to the reduction in TG accumulation independent of
FATP regulation.
We acknowledge that these two in vivo models may not be
completely translatable to human conditions such as type 2 and
type 1 diabetes, however, further evidence that insulin impacts the
FATP levels directly comes from our in vitro studies where targeted
gene disruption of IRS-1&2, led to decreased FATP-2&5
expressions. Though all in vitro experiments were not performed
under identical conditions (siRNA knockdown required an
additional 12 hours of incubation, resulting in a different
magnitude of TG accumulation) unlike in vivo, there is no
peripheral lipolysis in vitro, thus we concluded that increased
FATP expression at extremes of insulin concentrations is likely
mediated via imbalanced IRS signaling. We acknowledge that
some of the concentrations of insulin used (e.g. 100 mU/ml)
maybe be supraphysiological but they do provide for proof of
concept.
Indeed, others have also found that IRS-1 mRNA and protein
levels are increased with insulin treatment [8], and that IRS-2
mRNA is down regulated by insulin [44]. Thus, if a relative
increase of IRS-1 signaling is paramount in the pathogenesis of
obesity comorbidities, then a pharmacologic means of restoring
IRS-2 signaling might prove to be a viable therapeutic option.
White et al have reported that finding drugs which stimulate IRS-2
synthesis or promote its signaling might be a useful treatment
option for obesity-associated T2DM [45]. Similarly, Gupta et al.
have reported that the long-acting glucagon-like peptide 1 (GLP-1)
agonist, Exendin-4, decreases hepatic steatosis and activates the
same pathway as IRS-2 [46]. Also of note, insulin has been shown
in other tissues, such as cardiac myocytes and adipocytes, to
increase fatty acid uptake [18,47]. Furthermore, drugs used to
treat T2DM, which also improve hepatic steatosis, such as
rosiglitazone [48,49] and metformin [50], are found to preferen-
tially increase and restore IRS-2 expression.
The main finding of this report is that the amount of circulating
insulin is a major modulator of hepatic steatosis via regulation of
liver fatty acid transport proteins. In both in vitro and in vivo
experiments, insulin-mediated TG accumulation in the liver
exhibited a bimodal function, where both hypo and hyperinsuli-
nemia led to augmented liver fat storage. While we observed
reduced FATP 2 and 5 in these experiments, the reduction in TG
levels could also be attributable to enhanced fatty acid oxidation,
decreased de novo lipogenesis or altered lipoprotein export. These
pathways definitely need to be evaluated in future experiments in
order to understand the contribution of altered FFA uptake.
Ultimately, the sums of all of these processes appear to be
mediated via an imbalance of insulin substrates, where hypoinsu-
linemia is characterized by excessive IRS-2 signaling, and
hyperinsulinemia with predominant IRS-1 signaling. Regardless
as to which side the equilibrium is shifted; imbalanced insulin
signaling points to a common potential FATP response. The
identification and verification of this novel link in follow up
experiments may provide future therapeutic targets for the
treatment of obesity associated fatty liver disease.
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